Home › NDC Lookup › Ingredients › Trisodium Citrate Dihydrate › 23731-6030-01
triCitrasol Trisodium Citrate dihydrate 14 g/30mL Solution — NDC 23731-6030-01 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

triCitrasol Trisodium Citrate dihydrate 14 g/30mL Solution — NDC 23731-6030-1 (Billing 23731-6030-01)

by Citra Labs LLC · 10 VIAL, SINGLE-USE in 1 CASE / 30 mL in 1 VIAL, SINGLE-USE

This is a package of triCitrasol Trisodium Citrate dihydrate 14 g/30mL Solution from Citra Labs LLC, marketed since Jul 2003 and currently FDA-listed. It is the main listing for this product, which comes in 2 package sizes.

NDC 23731-6030-01
🏷️ FDA NDC (as labeled) 23731-6030-1 billing pads the package segment with a zero
This package
Contains30 mL in 1 vial, single-use Pack sizes2 compare ↓
Main listing for product 23731-6030 · Also comes in: 25 vials 23731-6030-2
Rx only Brand On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 8, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 23731-6030-1 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
23731 labeler · 6030 product · 1 package
Package marketed since
Jul 10, 2003
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 2373160301 3
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 23731-6030-1
Product NDC 23731-6030
11-digit billing NDC 23731603001
UNII B22547B95K
Application # BN010409
SPL Set ID 64e7652c-1437-43bd-8ea2-3cafab447b8c
Established class (EPC) Anti-coagulant; Calculi Dissolution Agent
Mechanism of action Acidifying Activity; Calcium Chelating Activity
Physiologic effect Decreased Coagulation Factor Activity
DEA schedule Non-controlled
Marketing category NDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2003-07-10
Route EXTRACORPOREAL
Dosage form SOLUTION
Substance TRISODIUM CITRATE DIHYDRATE

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 83400080101320
GPI class TriCitrasol
Quick answers
  • GPI-14 (Medi-Span): 83400080101320
Why two NDCs? The FDA registers this code as 23731-6030-1 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 23731-6030-01. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

Clinical

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly Not in the retail survey — common for institutional, discontinued, or low-volume packs.
Medicaid paysCMS SDUD · 12 mo No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data.
Medicare drug plans payPart D · quarterly No Part D plan price is available for this NDC in our data.
ℹ️
No price is published for this exact package yet. CMS surveys NADAC per package size, so a different pack of the same drug often has one.
Try another pack size: 25 vials
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Marketing startMarketing endStatus
23731-6030-01 You're viewing this Main listing 10 VIAL, SINGLE-USE in 1 CASE / 30 mL in 1 VIAL, SINGLE-USE 2003-07-10 — Active
23731-6030-02 23731-6030-2 25 VIAL, SINGLE-USE in 1 CASE / 30 mL in 1 VIAL, SINGLE-USE 2003-07-10 — Active

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 10 vial, single-use in 1 case / 30 ml in 1 vial, single-use.
What NDC number is used to bill for this package of triCitrasol Trisodium Citrate dihydrate 14 g/30mL Solution?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
triCitrasol 14 g/30mLthis 23731-6030-01 Citra 10 vials — — FDA listed —
About this product: this is the brand-name version. Some generic versions are approved by the FDA, but we could not confirm current pharmacy availability from our pricing/market data.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2003
On the market since
Jul 2003
📍
2026
Currently FDA-listed
23 years listed
🔒
·
Generic approved (availability unconfirmed)
see note
🔒Generic approved by FDA, but pharmacy availability is not confirmed

The FDA lists approved generic versions of this medicine, but that does not always mean a pharmacy can get one today. Patent rules, launch agreements, supply and pricing can affect when generics actually arrive.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

A current SPL was checked, but it does not contain a structured or narrative inactive-ingredient list for this product. This does not mean the product has no inactive ingredients.
Where does this data come from?
Source: official FDA Structured Product Labeling (SPL) via DailyMed and the openFDA label index. Structured IACT rows and label-wide narrative are kept separate; availability and product-level specificity depend on the submitted label.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerCitra Labs LLC
FDA applicationBN010409 (NDA)
Labeler code23731
First marketedJul 2003
Product typeHuman Prescription Drug
Portfolio2 products on file

More NDCs from Citra Labs LLC labeler code 23731

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications ⚠️ Warnings 🤒 Adverse Reactions 🔄 Drug Interactions 🤰 Pregnancy 🧒 Pediatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📚 References 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 158 words ▾

INDICATIONS AND USAGE triCitrasol ® Anticoagulant Sodium Citrate Concentrate, 46.7% Trisodium Citrate, is an anticoagulant used in granulocytapheresis procedures (granulocyte collection by apheresis). Just prior to performing granulocytapheresis, aseptically add 30 mL of triCitrasol ® to 500 mL of the 6% solution of Hydroxyethyl Starch (HES), e.g. Hespan ® 2-8 .

Agitate the resultant solution for 1 minute to assure a uniform concentration of anticoagulant. The resultant solution of triCitrasol ® and 6% solution of HES contains the following concentration depending upon the volume used: Volume of triCitrasol ® Volume of HES Total Volume Final Concentration of triCitrasol ® 30 mL 500 mL (measured from HES bag) 530 mL 2.6% 30 mL 558 mL (injected directly into HES bag) 588 mL 2.4% The triCitrasol ® /HES solution is stable for up to 24 hours at room temperature after mixing. Refer to the manufacturer's Operator's Manual of the apheresis medical device for the directions to perform the granulocytapheresis procedure.

⏱️ Dosage and Administration 41 words ▾

DOSAGE AND ADMINISTRATION The apheresis system will control the amount of the citrate/6% solution of HES that is added to the whole blood and the method of administration of the solution. Refer to the Operator's Manual of the apheresis medical device.

⛔ Contraindications 6 words ▾

CONTRAINDICATIONS NOT FOR DIRECT INTRAVENOUS INFUSION.

⚠️ Warnings 8 words ▾

WARNINGS CONCENTRATED ANTICOAGULANT – DILUTE PRIOR TO USE.

🤒 Adverse Reactions 130 words ▾

ADVERSE REACTIONS Citrate reactions or toxicity may occur with the infusion of blood products containing citrate anticoagulant 1. 9 11 . The recipient of the citrated blood product should be monitored for the signs and symptoms of citrate toxicity 1.

9 11 . The signs and symptoms of citrate toxicity begin with paresthesia, a "tingling" sensation around the mouth or in the extremities, followed by severe reactions that are characterized by chills, stomach cramps, or pressure in the chest, followed by more severe reactions that are characterized by hypotension and possible cardiac arrhythmia 1. 9 11 .

Citrate toxicity may occur more frequently in patients that are hypothermic 10 , have impaired liver or renal function 10 , or have low calcium levels because of an underlying disease 9 .

🔄 Drug Interactions 17 words ▾

Drug Interactions There are no adverse reactions for the addition of the product to the rouleaux agent.

🤰 Pregnancy 19 words ▾

Pregnancy Long-term studies in animals have not been performed to evaluate the effects of triCitrasol ® on pregnant women.

🧒 Pediatric Use 15 words ▾

Pediatric Use The safety and effectiveness of triCitrasol ® in children have not been established.

🆘 Overdosage 54 words ▾

OVERDOSAGE Since the bottle of triCitrasol ® contains only 30mL of the product, it is impossible to overdose the addition of the product to the 6% solution of HES. However, in the event of a reaction to the infusion of citrated blood products, evaluate the patient and institute appropriate corrective actions 1, 9 .

🧬 Clinical Pharmacology 33 words ▾

CLINICAL PHARMACOLOGY A sodium citrate solution acts as an anticoagulant by the action of the citrate ion chelating free ionized calcium; thus, the calcium ion is unavailable to the coagulation system 1 .

📦 How Supplied / Storage and Handling 65 words ▾

HOW SUPPLIED triCitrasol ® Anticoagulant Sodium Citrate Concentrate 46.7% Trisodium Citrate REF SIZE CASE PN 6030-25 30 mL Vial 25 Vials/Case PN 6030-10 30 mL Vial 10 Vials/Case It is recommended that the product be stored at ambient room temperature, 24°C (75°F); however, the product can be stored between 15°C (59°F) and 30°C (86°F). Protect from freezing and exposure to excessive heat should be minimized.

📦 Storage and Handling 37 words ▾

It is recommended that the product be stored at ambient room temperature, 24°C (75°F); however, the product can be stored between 15°C (59°F) and 30°C (86°F). Protect from freezing and exposure to excessive heat should be minimized.

📋 Description 56 words ▾

DESCRIPTION triCitrasol ® Anticoagulant Sodium Citrate Concentrate, 46.7% Trisodium Citrate, is a sterile, non-pyrogenic solution of Trisodium Citrate (Dihydrate), USP. Each 30 mL of concentrate contains: Trisodium Citrate, dihydrate, USP 14.0 grams Water for Injection, USP q.s. pH adjusted with Citric Acid pH: 6.3 –

6.6Single patient use only, on a single occasion. Chemical Structure

💬 Information for Patients 4 words ▾

Information for Patients None.

⚠️ Precautions 142 words ▾

PRECAUTIONS General Aseptic technique must be maintained at all times. triCitrasol ® Anticoagulant Sodium Citrate Concentrate is a clear/colorless solution. If the product shows any cloudiness or turbidity, the concentrate should be discarded. The cap/stopper system provides a biological barrier and should be intact – discard product if system is comprised.

Information for Patients None. Laboratory Tests There are no laboratory tests for the drug product at this time. Drug Interactions There are no adverse reactions for the addition of the product to the rouleaux agent.

Carcinogenesis, mutagenesis, impairment of fertility Long-term studies in animals have not been performed to evaluate the carcinogenic potential of triCitrasol ® . Pregnancy Long-term studies in animals have not been performed to evaluate the effects of triCitrasol ® on pregnant women. Pediatric Use The safety and effectiveness of triCitrasol ® in children have not been established.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 22 words ▾

Carcinogenesis, mutagenesis, impairment of fertility Long-term studies in animals have not been performed to evaluate the carcinogenic potential of triCitrasol ® .

📚 References ~1 min read ▾

REFERENCES Grindon, A. J., "Adverse Reactions to Whole Blood Donation and Plasmapheresis", CRC Crit. Rev Clin.

Lab. Sci ., 17 :51-75, 1982. Rock, G., and McCombie, N., "Alternate Dosage Regimens for High-Molecular-Weight Hydroxyethyl Starch", Transfusion , 25 :417-419, 1985.

Strauss, R. G., Hester, J. P., Vogler, W.R., Higby, D.

J., Snikeris, A. C., Imig, K. M., Greazel, C., Mallard, G., Burnett, D., Gupta, S., and Hulse, J.D., "A Multicenter Trial to Document the Efficacy and Safety of a Rapidly Excreted Analog of Hydroxyethyl Starch for Leukapheresis with a Note on Steroid Stimulation of Granulocyte Donors", Transfusion , 26 :258-264, 1986.

Strauss, R.G., Rohret, P.A., Randels, M. J., and Wihegarden, D. C., "Granulocyte Collection", J. of Clin.

Apheresis , 6 :241-243, 1991. Lee, J.H., and Klein, H. G., "The Effect of Donor Red Cell Sedimentation Rate on Efficiency of Granulocyte Collection by Centrifugal Leukapheresis", Transfusion, 35 :384-388, 1995.

Adkins, D., Ali., S. Despotis, G., Dynis, M. and Goodnough, L. T., "Granulocyte Collection Efficiency and Yield are Enhanced by the Use of a Higher Interface Offset During Apheresis of Donors Given Granulocyte-Colony-Stimulating Factor", Transfusion , 38 :557-564, 1998.

Jendiroba, D. B., Lichtiger, B., Anaissie, E., Reddy, V., O'Brien, S., Kantarjian, H., and Freireich, E. J., "Evaluation and Comparison of Three Mobilization Methods for the Collection of Granulocytes".

Transfusion , 38 :722-728, 1998. Leavey P. J., Thurman, G., and Anbruso, D.

R., "Functional Characteristics of Neutrophils Collected and Stored After Administration of G-CSF", Transfusion . 40 :414-419, 2000. AABB Technical Manual , 14 th Edition, page 590, 2001.

Denlinger, J.V., Nahrwold, M. L., Gibbs, P.S., and Lecky, J.H., "Hypocalcemia During Rapid Blood Transfusion in Anaesthetized Man", Br. J.

Anaesth ., 48 -995-1000, 1976. Stack, G., Judge, J.V., and Snyder, E.L., "Febrile and Nonimmune Transfusion Reactions", in Principles of Transfusion Medicine , pp. 780-781, editors Rossi, E.C., Simon, T.L., Moss, G.S., and Gould, S.A., Williams & Wilkins, Baltimore, MD, 2 nd ed., 1996.

📄 Package Label / Principal Display Panel ~1 min read ▾

PRINCIPAL DISPLAY PANEL - 10 Vial Case Label triCitrasol ® ANTICOAGULANT SODIUM CITRATE CONCENTRATE 46.7% Trisodium Citrate PN 6030 - 30 mL WARNING: CONCENTRATED ANTICOAGULANT Dilute prior to use NOT FOR DIRECT INTRAVENOUS INFUSION THIS CARTON CONTAINS 10 Sterile Units - 30 mL each Used with 6% Hydroxyethyl Starch 500 mL (diluent) for the Collection of Granulocytes by Apheresis. Do not use for other anticoagulant purposes. See package insert for directions for use.

Manufactured & Distributed by: Citra Labs ™ A Biomet Inc. Company. 55 Messina Drive, Braintree, MA 02184 ● USA Phone Number: 1-800-299-3411 Fax Number: 781-848-6781 Sterile ■ Non-Pyrogenic Composition per 30 mL of Concentrate: Trisodium Citrate (Dihydrate), USP 14.0 g (pH adjusted with Citric Acid) CAUTION: Single Procedure Use - Discard Unused Portion Do Not Use Unless Solution is Clear and Seal is intact Store Between 15°C - 30° C (59° F - 86° F) Rx only Exp: Lot: LA6030-10B 5/15 PRINCIPAL DISPLAY PANEL - 10 Vial Case Label

PRINCIPAL DISPLAY PANEL - 25 Vial Case Label triCitrasol ® ANTICOAGULANT SODIUM CITRATE CONCENTRATE 46.7% Trisodium Citrate PN 6030 - 30 mL WARNING: CONCENTRATED ANTICOAGULANT Dilute prior to use NOT FOR DIRECT INTRAVENOUS INFUSION THIS CARTON CONTAINS 25 Sterile Units - 30 mL each Used with 6% Hydroxyethyl Starch 500 mL (diluent) for the Collection of Granulocytes by Apheresis. Do not use for other anticoagulant purposes. See package insert for directions for use.

Manufactured & Distributed by: Citra Labs ™ A Biomet Inc. Company. 55 Messina Drive, Braintree, MA 02184 ● USA Phone Number: 1-800-299-3411 Fax Number: 781-848-6781 Sterile ■ Non-Pyrogenic Composition per 30 mL of Concentrate: Trisodium Citrate (Dihydrate), USP 14.0 g (pH adjusted with Citric Acid) CAUTION: Single Procedure Use - Discard Unused Portion Do Not Use Unless Solution is Clear and Seal is intact Store Between 15°C - 30° C (59° F - 86° F) Rx only Exp: Lot: LA6030-25B 5/15 PRINCIPAL DISPLAY PANEL - 25 Vial Case Label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

About this NDC listing & data coverage

Finished prescription product
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) — Not published for this NDC The labeler did not submit a structured excipient list, or no SPL is available.
NADAC pharmacy acquisition price (CMS) — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey.
Orange Book / therapeutic-equivalence data — Not published for this NDC Applies only to products approved under an NDA/ANDA; many listings are out of scope.
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold.
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

Why is there no price listed?
The pricing shown on our NDC pages comes from CMS NADAC, a voluntary survey of retail community pharmacy invoices. CMS does not publish a NADAC for every NDC — packages outside the retail survey (institutional and hospital products, bulk packages, discontinued items, and many OTC items) may never receive one. A missing price reflects the survey's scope, not this product's actual cost, and does not mean the product is free or unavailable.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Is this package still being marketed?
Yes, per the latest FDA NDC Directory data on this page: this package is listed as actively marketed, with no marketing end date reported by Citra Labs LLC. Listing status can change — the directory data on this page refreshes weekly.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 25 vials (23731-6030-02). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Citra Labs LLC is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 23667-0820-01 · Formulated 23731-6051-01 · Citra →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.